{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:39:50Z","timestamp":1791664790059,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.autrev.2020.102596","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:50:55Z","timestamp":1591962655000},"page":"102596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Risk of scleroderma according to the type of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"19","author":[{"given":"Benjamin","family":"Terrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure-H\u00e9l\u00e8ne","family":"Preta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Delage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Razanamahery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Laurent-Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Mestiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Beaudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Stolzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Blanche","family":"Valnet-Rabier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102596_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2020.102596_bb0010","first-page":"39","volume":"69","author":"Champiat","year":"2019","journal-title":"Rev Prat"},{"key":"10.1016\/j.autrev.2020.102596_bb0015","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2020.102596_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102596_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102596_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102456","article-title":"Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102596_bb0035","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with Cancer and Preexisting autoimmune disease: a Nationwide, Multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2020.102596_bb0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2020.102596_bb0045","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102596_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.autrev.2020.102596_bb0055","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by Pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2020.102596_bb0060","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2020.102596_bb0065","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1346-8138.14492","article-title":"Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma","volume":"46","author":"Cho","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2020.102596_bb0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2010.04.003","article-title":"PD-1, gender, and autoimmunity","volume":"9","author":"Dinesh","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102596_bb0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2020.102596_bb0080","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1346-8138.13339","article-title":"Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis","volume":"43","author":"Yanaba","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2020.102596_bb0085","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2020.102596_bb0090","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3389\/fimmu.2018.02998","article-title":"Targeting costimulatory pathways in systemic sclerosis","volume":"9","author":"Boleto","year":"2018","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:19:14Z","timestamp":1761599954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220301609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1568997220301609"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102596","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of scleroderma according to the type of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102596"}}